We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Alkemy Capital Investments Plc | LSE:ALK | London | Ordinary Share | GB00BMD6C023 | ORD GBP0.02 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.50 | 2.86% | 90.00 | 85.00 | 95.00 | 90.00 | 87.50 | 87.50 | 21,663 | 11:31:10 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Offices-holdng Companies,nec | 0 | -2.65M | -0.3239 | -2.78 | 7.35M |
From May 2022 to May 2024
TIDMALK TIDMB
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Søren Jelert, Executive Vice President, CFO and member of the Board of Management, has decided to resign his position to join a company in another sector and will expectedly leave ALK on 31 May 2023.
Chairman of the Board of Directors, Anders Hedegaard, and President & CEO, Carsten Hellmann said: "We would like to offer our sincere thanks to Søren for his pivotal role in ALK's transformation over the past five years. We wish him the best of luck in his future career."
A search for a new CFO has been initiated.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
Hot Features
Premium
-- FM_18_22UK_30112022
https://ml-eu.globenewswire.com/Resource/Download/b58450aa-fe21-4abf-bdb0-3ec56cc4b78f
(END) Dow Jones Newswires
November 30, 2022 11:24 ET (16:24 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Alkemy Capital Investments Chart |
1 Month Alkemy Capital Investments Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
